Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone

This phase 3, randomized controlled trial evaluated the effects of a combined 17β-estradiol and progesterone oral capsule (TX-001HR) on vasomotor symptoms (VMS), quality of life, and sleep in postmenopausal women. The study found that TX-001HR significantly reduced the frequency and severity of VMS, which was associated with improvements in quality